About: Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Respiratory Tract Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Respiratory Tract Disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Respiratory Tract Disease
Creator	Boeckh, Michael Cent, Anne Kuypers, Jane Kim, Yae-Jean Waghmare, Alpana Englund, Janet Falsey, Ann Walsh, Edward Guthrie, Katherine
Source	PMC
abstract	Background. Respiratory syncytial virus (RSV) lower respiratory tract disease (LRD) is a life-threatening complication in hematopoietic cell transplant (HCT) recipients. Lymphopenia has been associated with an increased risk of progression from upper respiratory tract infection (URI) to LRD. Methods. This study retrospectively analyzed the significance of lymphocyte engraftment dynamics, lung function, smoking history, corticosteroids, antiviral treatment, viral subtypes, and RSV-specific neutralizing antibodies for the progression to LRD in 181 HCT recipients with RSV URI. Results. In multivariable models, smoking history, conditioning with high-dose total body irradiation, and an absolute lymphocyte count (ALC) ≤100/mm(3) at the time of URI onset were significantly associated with disease progression. No progression occurred in patients with ALCs of >1000/mm(3) at URI onset. Lymphocyte engraftment dynamics were similar in progressors and nonprogressors. Pre- and posttransplant donor and posttransplant recipient RSV subtype-specific neutralizing antibody levels, RSV viral subtypes, and corticosteroids also were not significantly associated with LRD progression. Conclusions. Host and transplant related factors appear to determine the risk of progression to LRD more than viral factors. Dysfunctional cell-mediated immunity appears to be important in the pathogenesis of progressive RSV disease after HCT. A characterization of RSV-specific T-cell immunity is warranted.
has issue date	2013-12-23(xsd:dateTime)
bibo:doi	10.1093/infdis/jit832
bibo:pmid	24368837
has license	bronze-oa
sha1sum (hex)	b7aed141810c0294eae2351f9cfbfc6d0d06b96b
schema:url	https://doi.org/10.1093/infdis/jit832
resource representing a document's title	Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Factors Determining Progression to Lower Respiratory Tract Disease
has PubMed Central identifier	PMC3969549
has PubMed identifier	24368837
schema:publication	The Journal of Infectious Diseases
resource representing a document's body	covid:b7aed141810c0294eae2351f9cfbfc6d0d06b96b#body_text
is schema:about of	named entity 'Respiratory syncytial virus' named entity 'Hematopoietic' covid:arg/b7aed141810c0294eae2351f9cfbfc6d0d06b96b named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'COMPLICATION' named entity 'RISK OF' named entity 'LIFE' named entity 'INCREASED RISK' named entity 'HEMATOPOIETIC CELL' named entity 'CELL TRANSPLANT' named entity 'BACKGROUND' named entity 'PROGRESSION' named entity 'LOWER RESPIRATORY TRACT DISEASE' named entity 'ASSOCIATED WITH' named entity 'PROGRESSION' named entity 'HEMATOPOIETIC CELL' named entity 'CELL TRANSPLANT' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'LYMPHOPENIA' named entity 'LRD' named entity 'IS A' named entity 'UPPER RESPIRATORY TRACT INFECTION' named entity 'LOWER RESPIRATORY TRACT DISEASE' named entity 'TRANSPLANT RECIPIENTS' named entity 'Transplant' named entity 'URI' named entity 'upper respiratory tract infection' named entity 'URI' named entity 'URI' named entity 'URI' named entity 'antibody' named entity 'RSV' named entity 'statistically significant effect' named entity 'URI' named entity 'serum' named entity 'TBI' named entity 'risk factors' named entity 'GVHD' named entity 'antigen' named entity 'life-threatening disease' named entity 'lymphocyte count' named entity 'staining' named entity 'RSV infection' named entity 'RSV' named entity 'RSV' named entity 'URI' named entity 'multiple comparisons' named entity 'risk factor' named entity 'RSV' named entity 'lower respiratory tract' named entity 'cGy' named entity 'RSV' named entity 'biopsy' named entity 'URI' named entity 'corticosteroid' named entity 'adenovirus' named entity 'lymphocyte' named entity 'cough' named entity 'RT-PCR' named entity 'URI' named entity 'serum' named entity 'immunocompromised' named entity 'immunoglobulin' named entity 'pulmonary disease' named entity 'statistical significance' named entity 'bronchoalveolar lavage' named entity 'transplant recipients' named entity 'Fred Hutchinson Cancer Research Center' named entity '21%' named entity 'ribavirin' named entity 'protein' named entity 'URI' named entity 'IRIS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software